Drugs Made In America Acquisition Corp. (DMAAU) Notes Payables (2024 - 2025)
Drugs Made In America Acquisition's (DMAAU) quarterly Notes Payables came in at $60898.0 in Q1 2025, down 90.81% on a QoQ basis from $662324.0 in Q4 2024.
Drugs Made In America Acquisition Corp. (DMAAU) Notes Payables (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAU) has 2 years of Notes Payables data on file, last reported at $60898.0 in Q1 2025.
- Quarterly Notes Payables changed N/A year-over-year to $60898.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $60898.0 (changed N/A YoY) and the FY2024 annual result came in at $662324.0, changed N/A from the prior year.
- Notes Payables declined to $60898.0 in Q1 2025, from $662324.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $662324.0 in Q4 2024 to a low of $60898.0 in Q1 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 60,898.00 |
| Dec 31, 2024 | 662,324.00 |